James C. Paulson

This paper describes the development and cGMP manufacturing of an HIV vaccine candidate for clinical trials, demonstrating scalable production and quality control.

The study assesses the pandemic risk of a fatal zoonotic H3N8 influenza virus from chickens, finding it has moderate pandemic potential due to its ability to infect humans and replicate in human cells.

The paper shows H3N2 influenza viruses preferentially bind to tracheal ciliated cells due to specific glycan receptors.

Membrane-bound BG505 MD39.3 Env trimer delivered as mRNA-LNP reduced base-directed antibody responses in rabbits and macaques and elicited neutralizing antibodies, with memory B cell responses documented in macaques.

The paper examines how mutations and a deletion in the KP.3.1.1 SARS-CoV-2 spike protein affect ACE2 binding and antibody escape, revealing structural and functional insights into its evolution.

The paper presents a nanodisc platform for assembling transmembrane glycoproteins into vaccine candidates, demonstrating its utility in HIV vaccine development through structural and functional analyses.

This study develops a degrader for Siglec-7 and -9 to reshape the tumor microenvironment and enhance T cell anti-tumor immunity in murine models.

This study shows that clade 2.3.4.4b H5N1 influenza viruses bind efficiently to avian-type sialic acid receptors but not human-type receptors.

The paper maps O-glycosylation sites on SARS-CoV-2 spike protein produced in insect and human cells, identifying 25 sites with distinct patterns between ectodomains and RBD.